| Literature DB >> 31490946 |
Benjamin L Johnson1,2, Marcela d'Alincourt Salazar1, Sarah Mackenzie-Dyck1, Massimo D'Apuzzo3, Hung Ping Shih4, Edwin R Manuel5, Don J Diamond1.
Abstract
The five-year survival rate of patients diagnosed with advanced pancreatic ductal adenocarcinoma (PDAC) has remained static at <5% despite decades of research. With the exception of erlotinib, clinical trials have failed to demonstrate the benefit of any targeted therapy for PDAC despite promising results in preclinical animal studies. The development of more refined mouse models of PDAC which recapitulate the carcinogenic progression from non-neoplastic, adult exocrine subsets of pancreatic cells to invasive carcinoma in humans are needed to facilitate the accurate translation of therapies to the clinic. To study acinar cell-derived PDAC initiation, we developed a genetically engineered mouse model of PDAC, called KPT, utilizing a tamoxifen-inducible Cre recombinase/estrogen receptor (ESR1) fusion protein knocked into the Ptf1a locus to activate the expression of oncogenic KrasG12D and Trp53R270H alleles in mature pancreatic acinar cells. Oncogene-expressing acinar cells underwent acinar-to-ductal metaplasia, and formed pancreatic intraepithelial neoplasia lesions following the induction of oncogene expression. After a defined latency period, oncogene-expressing acinar cells initiated the formation of highly differentiated and fibrotic tumors, which metastasized to the lungs and liver. Whole-transcriptome analysis of microdissected regions of acinar-to-ductal metaplasia and histological validation experiments demonstrated that regions of acinar-to-ductal metaplasia are characterized by the deposition of the extracellular matrix component hyaluronan. These results indicate that acinar cells expressing KrasG12D and Trp53R270H can initiate PDAC development in young adult mice and implicate hyaluronan deposition in the formation of the earliest characterized PDAC precursor lesions (and the progression of pancreatic cancer). Further studies are necessary to provide a comprehensive characterization of PDAC progression and treatment response in KPT mice and to investigate whether the KPT model could be used as a tool to study translational aspects of acinar cell-derived PDAC tumorigenesis.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31490946 PMCID: PMC6731019 DOI: 10.1371/journal.pone.0221810
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Top 10 signaling pathways associated with PDAC in the KPT mice (A) and humans [36] (B), compared to normal murine or human pancreas, respectively.
There is a 50% overlap (bold) between the top 10 signaling pathways in the KPT mice and humans, including the top pathway hit.
| A) KPT PDAC | -Log | Ratio | B) Human PDAC | -Log | Ratio |
|---|---|---|---|---|---|
| 10.517 | 0.235 | 7.07 | 0.186 | ||
| 7.053 | 0.185 | 5.22 | 0.308 | ||
| 3. Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis | 6.463 | 0.176 | 4.93 | 0.151 | |
| 5.804 | 0.182 | 4. Antigen Presentation Pathway | 4.68 | 0.297 | |
| 5.157 | 0.173 | 5. Complement System | 4.68 | 0.297 | |
| 6. Retinol Biosynthesis | 5.08 | 0.31 | 6. Leukocyte Extravasation Signaling | 4.59 | 0.152 |
| 7. Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 4.629 | 0.144 | 4.41 | 0.153 | |
| 3.973 | 0.282 | 8. Cell Cycle Control of Chromosomal Replication | 4.36 | 0.333 | |
| 9. Axonal Guidance Signaling | 3.711 | 0.124 | 4.15 | 0.148 | |
| 10. Valine Degradation I | 3.667 | 0.389 | 10. Mitotic Roles of Polo-Like Kinase | 3.98 | 0.212 |
The expression of hyaluronan related genes is increased in regions of ADM.
Differential gene expression analysis comparing ADM and HP sample sets identifies HA related genes. Significance is defined as log2 (fold change) > 1 and an adjusted P value < 0.001, all else is defined as not significant (NS).
| Gene Category | Gene Name | Gene Symbol | log2 (Fold Change) | Adjusted | HP VS ADM (Up/NS) |
|---|---|---|---|---|---|
| Hyaluronan Synthase | Hyaluronan Synthase 1 | Has1 | 2.43 | 1.09E-02 | NS |
| Hyaluronan Synthase 2 | Has2 | 4.10 | 2.52E-09 | Up | |
| Hyaluronan Synthase 3 | Has3 | 1.87 | 4.01E-05 | Up | |
| Hyaluronidase | Hyaluronoglucosaminidase 1 | Hyal1 | 0.70 | 4.52E-03 | NS |
| Hyaluronoglucosaminidase 2 | Hyal2 | 1.31 | 3.01E-08 | Up | |
| Hyaluronoglucosaminidase 3 | Hyal3 | -1.00 | 1.52E-01 | NS | |
| Hyaluronan Receptor | CD44 Molecule (Indian Blood Group) | Cd44 | 5.35 | 1.83E-120 | Up |
| Hyaluronan Mediated Motility Receptor | Hmmr | 1.28 | 2.14E-03 | Up | |
| Stabilin 2 (Hyaluronan Receptor For Endocytosis) | Stab2 | 3.89 | 8.80E-04 | Up |